Patent expiry and biosimilars (revision 28)

Patent protection and regulatory exclusivity together determine when a competitor may market a copy of an approved product. When both lapse, entry becomes possible by one of two routes: as a generic, demonstrating that the active substance is the same, or as a biosimilar, demonstrating high similarity through a comparability exercise.^[1]

Synthetic peptides sit awkwardly between the categories. They are made by chemical synthesis like small molecules, but are large enough that impurity profiles and higher-order structure may differ between manufacturers in ways a small-molecule generic pathway was not designed to address.^[2]

Which pathway applies differs by jurisdiction and by molecule, and guidance specific to synthetic peptide generics has been issued to address exactly this.^[3]

A generic application demonstrates that the active substance is the same as the reference product and that the finished product is bioequivalent. No clinical efficacy trial is generally required.^[1]

A biosimilar application demonstrates high similarity through analytical comparability, supported by pharmacokinetic and, where necessary, clinical data. The bar is similarity rather than identity, because biological manufacture cannot produce identity.^[1]

For a synthetic peptide, identity of the active substance is in principle demonstrable, which points to the generic pathway. What complicates it is that impurities differ between synthetic routes, and an impurity absent from the reference product raises questions a bioequivalence study does not answer.^[3]

Guidance for synthetic peptide generics focuses on the impurity profile: a proposed generic must show that any impurity not present in the reference product, or present at higher level, does not raise a safety or immunogenicity concern.^[3]

This is the same argument that runs through the analytical articles on this wiki. Peptide impurities are structurally close to the peptide, are route-dependent, and are what an adequately specific method exists to resolve. See Solid-phase peptide synthesis.^[2]

The consequence is that a peptide generic is a more analytically demanding application than a small-molecule generic, and the analytical package rather than the clinical one carries the argument.^[3]

Patent expiry changes the commercial landscape rather than the chemistry. A molecule whose protection has lapsed can be made and sold lawfully by anyone able to meet the regulatory requirements, and prices fall accordingly. See Cost per milligram.^[1]

It does not change the status of research-chemical supply, which is a separate category question: material sold as a reagent is not a medicine regardless of whether the reference product is still protected. See Regulatory status by jurisdiction.^[2]

Nor does it change what a certificate establishes. The impurity argument above applies with more force outside licensed supply, not less, because there is no comparability exercise at all.^[4]

• Cost per milligram
• Regulatory status by jurisdiction
• Active pharmaceutical ingredient
• Analytical method validation
• Solid-phase peptide synthesis